Overview

A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety, tolerability, and efficacy of two dose regimens of PF-3463275 compared with placebo added to ongoing atypical antipsychotic therapy for cognitive deficits in subjects with chronic symptoms of schizophrenia.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer